Physician profile
Bryan Daniel Gray
NPI 1831514025
$55,485.80
in general payments reported to CMS, 2019-2025
42 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $759 · 2021: $1,630 · 2022: $2,199 · 2023: $7,740 · 2024: $3,700 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $10K · Consulting Fee: $5,200 · Travel and Lodging: $2,294 · Education: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,612.50 |
| Food and Beverage | $10,410.92 |
| Consulting Fee | $5,200.00 |
| Travel and Lodging | $2,294.45 |
| Education | $614.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32,913.63 | 2020-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $6,126.88 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $2,979.49 | 2019-2025 | |
| Incyte Corporation | $2,908.29 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $2,207.96 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $882.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $808.45 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $711.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $565.99 | 2022-2025 | Sotyktu |
| Pfizer INC. | $539.52 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.82 | 2022-2025 | Spevigo, Cyltezo |
| Leo Pharma INC. | $512.68 | 2023-2025 | Adbry, Spevigo |
| Ucb, INC. | $421.26 | 2019-2025 | Bimzelx, Cimzia |
| Celgene Corporation | $420.54 | 2019 | |
| Dermavant Sciences, INC. | $391.31 | 2022-2024 | Vtama |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339.34 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $262.87 | 2023-2025 | Zoryve |
| Organogenesis INC. | $250.98 | 2020-2025 | Puraply, Cygnus Dual, Nushield |
| Mimedx Group, INC. | $208.54 | 2024-2025 | |
| Microaire Surgical Instruments LLC | $207.92 | 2025 | |
| Galderma Laboratories, L.P. | $162.30 | 2021-2025 | Nemluvio |
| Verrica Pharmaceuticals INC. | $149.85 | 2024-2025 | Ycanth |
| Biofrontera INC. | $110.63 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $101.19 | 2021 | |
| Janssen Scientific Affairs, LLC | $87.50 | 2022 | |
| Strata Skin Sciences, INC. | $78.16 | 2020-2025 | Xtrac |
| Kyowa Kirin, INC. | $76.11 | 2020-2023 | Poteligeo |
| Almirall LLC | $61.76 | 2022-2023 | Seysara |
| Organon LLC | $44.55 | 2025 | Vtama |
| Bioventus LLC | $41.00 | 2022-2023 | |
| Smith+Nephew, INC. | $40.67 | 2024-2025 | Grafix Pl |
| Genentech USA, INC. | $35.19 | 2021-2024 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $34.55 | 2021-2023 | Valchlor |
| Convatec INC. | $31.41 | 2025 | |
| Botanix Sb INC | $31.05 | 2025 | Sofdra |
| Chiesi USA, INC. | $23.94 | 2024 | Filsuvez |
| Vertex Pharmaceuticals Incorporated | $23.59 | 2025 | |
| Kerecis Limited | $20.50 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Mylan Institutional INC. | $20.02 | 2023 | Hulio |
| Paratek Pharmaceuticals, INC. | $14.05 | 2024 | Nuzyra |
| Melinta Therapeutics, LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.